| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 435.16B | 400.28B | 371.62B | 324.16B | 287.60B | 257.14B |
| Gross Profit | 85.73B | 89.40B | 90.96B | 79.62B | 69.65B | 67.00B |
| EBITDA | 30.52B | 28.08B | 36.33B | 31.84B | 27.07B | 25.30B |
| Net Income | 17.59B | 14.40B | 22.38B | 20.12B | 17.29B | 15.40B |
Balance Sheet | ||||||
| Total Assets | 315.27B | 298.28B | 273.72B | 245.71B | 212.21B | 197.29B |
| Cash, Cash Equivalents and Short-Term Investments | 30.61B | 29.11B | 29.63B | 27.91B | 23.91B | 19.78B |
| Total Debt | 80.14B | 76.90B | 67.44B | 57.62B | 46.00B | 43.47B |
| Total Liabilities | 209.46B | 195.69B | 174.80B | 159.36B | 135.73B | 126.75B |
| Stockholders Equity | 95.79B | 92.66B | 88.76B | 77.77B | 71.76B | 65.49B |
Cash Flow | ||||||
| Free Cash Flow | 17.37B | 20.70B | 25.68B | 23.40B | 19.89B | 20.12B |
| Operating Cash Flow | 20.96B | 24.20B | 29.07B | 26.21B | 22.34B | 22.17B |
| Investing Cash Flow | -7.19B | -20.53B | -15.57B | -28.48B | -10.37B | -12.53B |
| Financing Cash Flow | -18.95B | -3.51B | -11.53B | 4.23B | -7.46B | -3.59B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | $75.71B | 13.93 | 12.61% | 2.01% | 11.96% | -11.11% | |
72 Outperform | $296.59B | 17.09 | 18.48% | 2.67% | 10.48% | 24.25% | |
71 Outperform | $8.41B | 10.15 | 19.71% | ― | 13.71% | -18.02% | |
69 Neutral | $31.20B | 24.31 | 7.15% | 1.36% | 9.87% | -5.58% | |
64 Neutral | $98.66B | 203.08 | 0.63% | 3.42% | 6.71% | -90.11% | |
58 Neutral | $19.18B | -3.61 | -21.93% | ― | 14.92% | -286.72% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
On November 18, 2025, UnitedHealth Group announced the appointment of Scott Gottlieb, M.D. as an independent director. Dr. Gottlieb, known for his tenure as FDA commissioner from 2017 to 2019, is recognized for his efforts in promoting transparency, patient safety, and medical innovation. His appointment is expected to bring valuable insights to UnitedHealth, given his extensive experience in healthcare policy and regulation.
On November 6, 2025, UnitedHealth Group’s Board of Directors approved an amendment to the company’s bylaws to update its registered office and agent in Delaware. This administrative change is expected to streamline the company’s operations and ensure compliance with state regulations.
UnitedHealth Group announced that its senior leaders will participate in the UBS Global Healthcare Conference 2025 on November 10, 2025. They will discuss the company’s strategy, market positions, recent results, and expectations for its end markets, which could impact its operations and industry positioning.